secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-203993
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026
--------------------------------------------------------------------------------

- Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.
- Cash and investments $419.7M as of March 31, 2026, including $59.9M from ATM. Expected runway into 2H 2028.
- Enrolled Phase 1b enozertinib monotherapy in 1L EGFR exon20 insertion NSCLC; data expected 2H 2026.
- R&D expenses $31.4M in Q1 2026 vs $24.6M in Q1 2025, driven by rinzimetostat and enozertinib advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/0001193125-26-203993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/oric-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-203993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer